[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"German University in Cairo\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":127},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,77,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100623256","phase-2-effect-of-add-on-l-arginine-therapy-on-heart-failure-patients-100623256",false,"NCT07394270","Effect of Add-on L-Arginine Therapy on Heart Failure Patients","Effect of Add-on L-Arginine Therapy on Clinical Outcome of Heart Failure Patients: A Randomized- Controlled Trial","Inclusion Criteria:\n\n* Patients with EF \\\u003C40%\n* eGFR \\>30 mL\u002Fmin\u002F1.73 m2\n* Stable patients\n* Capable and willing to provide written consent\n\nExclusion Criteria:\n\n* Patients with implantable cardioverter-defibrillator\n* Pregnant or lactating fmeales\n* Patients with a history of sensitivity to L-Arginine or any of the excipients\n* Acute heart failure patients\n* Patients use L-arginine supplementation.\n* Patients with active herpes disease","ALL","19 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Heart failure is considered one of the greatest challenges globally. There are various treatment strategies for heart failure. L-Arginine is an amino acid that was found to have beneficial effect on vasculature. This study aims to study the benefits and side effects of using L-arginine on the patients with ejection fraction \\\u003C40%",[26],"Heart Failure",[28,29,30,31,32],"Heart failure","Drug repurposing","L-Arginine","Add-on therapy","HFrEF","NOT_YET_RECRUITING","2026-02-01",{"date":36,"type":37},"2026-02-06","ACTUAL",{"date":39,"type":20},"2026-02",{"date":41,"type":20},"2027-07",{"name":43,"class":44},"German University in Cairo","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":45},"100618981","phase-2-evaluation-of-the-effect-of-l-arginine-on-the-cognitive-function-in-geriatric-patients-100618981","NCT07338682","Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients","Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients, A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age \\>60 years\n* Montreal Cognitive Assessment (MoCA) test score from 10-25 (mild to moderate cognitive impairment)\n\nExclusion Criteria:\n\n* Presence of neurodegenerative diseases (e.g.: Alzheimer's disease, Parkinson's disease, Huntington's disease, Multiple Sclerosis)\n* Patients with history of L-arginine intolerance or allergy\n* Patients with asthma\n* Patients who recently had an acute myocardial infarction\n* Patients with history of stroke within 1 yaear\n* Patients who started or discontinued medications that may affect cognitive function (e.g., CNS psychotropics, antihistamines, or acetylcholinesterase inhibitors) during the study period.\n* Patients who initiated or stopped antihypertensive medications during the study period.\n* Patients who initiated or stopped antidiabetic medications during the study period.\n* Patients who initiated or stopped antihyperlipidemic medications during the study period.\n* Patients prescribed medications for depression, anxiety, or stress that may impact cognitive function\n* Patients on nitrates, phosphodiesterase-5 inhibitors, potassium sparing diuretics\n* Refusal to provide written informed consent","60 Years",{"count":55,"type":20},60,[23],"This study aims to evaluate the effect of L-arginine supplementation on cognitive function in geriatric patients. Eligible participants will receive either L-arginine (6 grams once daily) or placebo, and their cognitive performance will be assessed using validated cognitive assessment tools over the study period. The participants will receive the intervention for 4 weeks and followed up every 2 weeks. The primary outcome is improvement in cognitive function, while secondary outcomes include safety, tolerability, and quality of life measures. The findings may provide evidence for the potential role of L-arginine in supporting cognitive health in elderly populations.",[59,60],"Cognition Disorders in Old Age","Cognitive and Behavioral Impairment",[62,63,64,65,66,67],"L-arginine","Cognitive impairment","Geriatrics","Elderly","Cognitive Function","Nitric Oxide","RECRUITING","2026-01-18",{"date":71,"type":37},"2026-01-21",{"date":73,"type":37},"2025-08-27",{"date":75,"type":20},"2026-06-30",{"name":43,"class":44},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":53,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":45},"100573998","phase-2-l-carnitine-supplementation-in-rheumatoid-arthritis-patients-100573998","NCT06753565","L-carnitine Supplementation in Rheumatoid Arthritis Patients","Effect of L-carnitine Supplementation on Disease Activity in Rheumatoid Arthritis Patients","Inclusion Criteria:\n\n* age between 18-60 years old\n* diagnosed of rheumatoid arthritis according to 2010 American College of Rheumatology\u002FEuropean League Against Rheumatism criteria for at least 6 months\n* enrolled patients treated with one of more of conventional DMARDs for ≥ 6 months with stable dose for ≥ 1 month before start of the study\n* active RA despite conventional DMARDs treatment (DAS28 ESR more than or equal 3.2)\n* patient or legal representative should sign informed consent\n\nExclusion Criteria:\n\n* pregnant or lactating female\n* patients with liver dysfunction (\\>1.5x the upper limit of normal value for ALT \\& AST)\n* Patients with kidney dysfunction (serum creatinine more than 1.2 mg\u002Fdl)\n* Patients with any active infection or concurrent malignancy\n* patients with uncontrolled medical conditions or other rheumatic diseases\n* patients currently taking drugs that could interact with carnitine like: warfarin","18 Years",{"count":55,"type":20},[23],"This study aims to evaluate the effect of l-carnitine as add- on therapy for improving the outcome in rheumatoid arthritis patients.",[89],"Rheumatoid Arthritis (RA)",[91,92,93,94,95,96],"Rheumatoid Arthritis","Carnitine","anti-inflammatory","anti-oxidant","ACR50%","disease activity","2025-01-04",{"date":99,"type":37},"2025-01-07",{"date":101,"type":37},"2024-12-31",{"date":103,"type":20},"2025-06",{"name":43,"class":44},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100551330","phase-1-effect-of-vitamin-d-supplementation-on-mental-health-an-exploratory-study-on-a-university-students-suffering-from-vitamin-d-deficiency-100551330","NCT06458686","Effect of Vitamin D Supplementation on Mental Health: An Exploratory Study on A University Students Suffering From Vitamin D Deficiency","Inclusion Criteria:\n\n* For phase 1: sample will be selected using convenient sampling method where all students with an age range 18-22 years old fulfilling the eligibility criteria will be educated about the study protocol and will be asked to participate in the study.\n\nFor phase 2: students who diagnosed with deficient vitamin D level will be asked to participate in the study.\n\nExclusion Criteria:\n\n* Hypersensitivity to oral vitamin D supplements such as Diviton or Vidrop.\n\n  * Students taking medications affecting vitamin D metabolism such as anti-seizure medications: phenytoin, phenobarbital and carbamazepine, isotretinoin, steroids: dexamethasone, antibiotics: isoniazid and rifampin and antifungals: clotrimazole.\n  * Students taking antidepressants, drug for bipolar disorder treatment like lithium and antipsychotic agents like olanzapine.\n  * Students with insufficient vitamin D level (20-30 ng\u002FmL).\n  * Students with confirmed diagnosis with psychiatric illness.\n  * Students with a history of liver disease or dysfunction.\n  * Students with a history of kidney disease or dysfunction.","22 Years",{"count":113,"type":20},70,[115,23],"PHASE1","University students are susceptible to psychological burdens such as depressive symptoms, anxiety, and stress which might have been linked to vitamin D deficiency. Low serum vitamin D level is well recognized around the world. Vitamin D has been reported to modulate several neurological pathways in the brain that control psychological function. As a result, the purpose of this study is to evaluate the effect of vitamin D supplementation on the presence of depressive symptoms, anxiety, and stress in university students. The study will include two phases. The first phase is a cross-sectional phase assessing the prevalence vitamin D deficiency in addition to psychological symptoms. The second phase is a randomized controlled clinical trial that aims to assess the effect of vitamin D supplementation on the prevalent psychological symptoms and its impact on the academic performance among university students. The study will look at the relationship between mental health and vitamin D deficiency, as well as how it will affect academic performance of university students.",[118],"Psychiatric Disorder","2024-06-09",{"date":121,"type":37},"2024-06-13",{"date":123,"type":20},"2024-06-30",{"date":125,"type":20},"2026-09-30",{"name":43,"class":44},""]